Product information and disease descriptionPlace of product in therapyApproaches to treatmentCurrent treatment options and standard of care
Limitations of current therapies
8 evidence topics · 11 sources
Summary
- Administration frequency of first-line prophylaxis ranges from twice weekly (subcutaneous plasma-derived C1 inhibitor, every 3 or 4 days) and once daily (oral berotralstat) to every 2 weeks (lanadelumab, with every 4 weeks considered after more than 6 months of good control), monthly after a 400 mg loading dose (garadacimab), and every 4 or 8 weeks (donidalorsen). Intravenous C1 inhibitor requires venous access and has a “high cost” and “frequent administrations due to its short half-life”.
- Attacks “can still occur even in patients under LTP”. Berotralstat achieved an approximately 50% reduction in attack rate in its pivotal trial, and donidalorsen every 4 and 8 weeks reduced attacks by 81% and 55%, respectively, compared with placebo. Berotralstat, lanadelumab, and donidalorsen have a delayed onset of protection.
- In US commercial claims, 55% of patients had refill gaps, discontinued, or switched prophylaxis within a year of initiation, and on-demand treatment use “remained present for over two-thirds of patients”. A second study reported that annualized expenditures for on-demand prescriptions, hospitalizations, and emergency department visits averaged more than $200,000 after subcutaneous prophylaxis began.
- No head-to-head trials of prophylactic agents have been published; a Cochrane review stated that this “prevented us from drawing firm conclusions on the relative efficacy of the drugs”, and indirect comparisons favor lanadelumab and C1 inhibitor over berotralstat.
- About 50% of patients receive long-term prophylaxis, even in high-income countries, and the higher costs of newer agents limit their availability.
- Second-line attenuated androgens are associated with virilization in women, dyslipidemia, and hepatotoxicity, cannot be used in pregnancy or in children and adolescents, and require semi-annual laboratory monitoring with annual liver ultrasound; tranexamic acid shows “mediocre efficacy in HAE-C1-INH”.
Attacks during prophylaxis and comparative evidence: guideline statements
“Attacks can still occur even in patients under LTP, and on-demand medication must remain available to them.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Although no direct comparisons between therapies have been published, indirect comparisons and a Cochrane analysis favor lanadelumab and C1-INH as LTP over berotralstat in terms of efficacy.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Uptake of prophylaxis and cost as a barrier to access
“Nevertheless, even with recent advances, LTP is still not the standard of care, even in high-income countries, with only about 50% of patients currently receiving it.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Despite their greater effectiveness, newer drugs are associated with higher costs that clearly limit their availability, particularly in low- and middle-income countries.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Delayed onset of protection: pediatric guideline
Persistence, switching, and on-demand use after starting prophylaxis: US claims
“This study found that 55% of patients had refill gaps in LTP claims, discontinued, or switched LTP within a year of initiation.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Even with use of LTP, on-demand treatment utilization remained present for over two-thirds of patients.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Adherence and persistence after starting targeted prophylaxis: US linked health records and claims
“Primary study measures were adherence, defined as the mean proportion of days covered (PDC), and persistence, defined as having no gap in treatment ≥ 45 days after the LTP initiation date.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The main analysis included 357 patients (90 on berotralstat, 189 lanadelumab, and 78 SC-pdC1-INH).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Adherence (mean PDC) was similar between treatments at 0.73, 0.78, and 0.74 for berotralstat, lanadelumab, and SC-pdC1-INH, respectively.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Proportions of patients persistent on index LTP after 12 months were similar across LTPs: 61%, 58%, and 53% for berotralstat, lanadelumab, and SC-pdC1-INH, respectively.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote